No Data
No Data
Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call
Nanobiotix Updates Voting Rights and Share Capital as of March 2025
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Nanobiotix (NBTX) and IQVIA Holdings (IQV)
UBS Initiates Nanobiotix(NBTX.US) With Hold Rating, Announces Target Price $3.5
Nanobiotix SA's Positive Earnings Call Highlights Strategic Growth
Guggenheim Maintains Nanobiotix(NBTX.US) With Buy Rating, Cuts Target Price to $8